Gelonghui, April 10 | Eling Pharmaceutical (002603.SZ) said on an interactive platform that Jinlida granules have not conducted clinical research on “weight loss” indications. In 2015, the “Randomized, double-blind, placebo-controlled, multicenter clinical trial of efficacy and safety of metformin monotherapy patients treated with metformin after taking Jinlida granules” led by the Chinese Academy of Traditional Chinese Medicine Guanganmen Hospital and the Chinese Medicine Laboratory of the University of Chicago in the US was published in “Plos One” magazine. The results showed that on the basis of diet control, exercise therapy, and metformin dose stabilization treatment, combined use of fasting Jinlida granules can reduce HbA1c and lower blood sugar in patients At the same time improving the patient's Insulin resistance, increases insulin sensitivity and beta cell function index, improves patients' clinical symptoms, reduces weight, and is safe.